Photocure (PHO)
Oslo Stock Exchange · Norway · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 49.00 |
|---|---|
| 52-week range | 46.25 – 79.80 |
| Return, 1 month / 3 months | −5.6% / −13.1% |
| Return, 1 year / 3 years | −4.5% / −6.3% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 41.3% |
| Worst drawdown (1 year) | -39.1% |
| Average daily value traded | 3.61M NOK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Photocure is a pharmaceutical company based in Oslo, Norway, that develops and supplies products for the detection and management of bladder cancer. Its main offering is a diagnostic agent used during cystoscopy, a procedure in which urologists examine the bladder with a special light system to find tumours. The company serves hospitals, clinics and medical specialists who diagnose and monitor patients with the disease. Photocure also works on related technology and products for urology and cancer care.
On this site Photocure appears as a stock on the Oslo Stock Exchange (Norway), code PHO, with prices in Norwegian kroner (NOK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Photocure (PHO) trades on the Oslo Stock Exchange in Norway. It last closed at NOK 49.00 on 23 October 2026.
Its price-based Market X-Ray is 32 out of 100 (a weak price profile), ranking 221 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 4.5% and over the last three months it fell 13.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 20 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -18.8% | ||
| From 52-week high | -38.0% | ||
| Momentum | 26 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -13.1% | ||
| 6-month return | -29.6% | ||
| 12-month return, skipping the last month | 1.2% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.1% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.61M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.5% |
|---|---|
| 1 month | −5.6% |
| 3 months | −13.1% |
| 6 months | −29.6% |
| 1 year | −4.5% |
| 3 years | −6.3% |
| 5 years | −59.1% |
Signals
| 50-day / 200-day average | 51.73 / 60.33 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.26 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.